Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Airlines Group Inc (AAL) vs TransMedics Group Inc (TMDX) Price & Performance

American Airlines Group IncTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

American Airlines Group Inc vs TransMedics Group Inc — how do they compare? American Airlines Group Inc trades at $14.98 (market cap $10.55B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: American Airlines Group Inc is far larger — about 3.4× TransMedics Group Inc's market cap, and American Airlines Group Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.

AALTMDX
Market Cap
$10.55B$3.10B
Sector
IndustrialsTechnology
52-Week High
$18.15$150.42
52-Week Low
$10.18$61.99
Enterprise Value
$38.51B$3.49B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Airlines Group Inc

American Airlines (AAL) trades at $14.94, down 0.43% with a bearish technical signal. The company shows mixed fundamentals with strong revenue growth but negative net income margin (-0.56%) and elevated P/E of 43.73. Recent Q2 2026 earnings beat expectations with $0.15 EPS versus $0.03 expected, while Q4 2025 missed estimates. Cash flow remains positive with $154M net cash flow in 2025. Analyst consensus is mixed with 44.7% buy ratings and $19.63 price target, representing 31% upside.

AAL presents a turnaround opportunity with premium revenue growth and debt reduction, but faces significant headwinds from fuel costs and negative equity. The stock trades below analyst targets but requires sustained profitability improvement to justify current valuation multiples. Key risks include fuel price volatility and competitive pressure in the airline industry.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.

The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Airlines Group Inc

American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.

Read more on AAL

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX